medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2015-13-118-123medsovet-347Research ArticleОбзорыReviewsПоражение почек у пациентов с неалкогольной жировой болезнью печени и хронической сердечной недостаточностьюRenal disease in patients with nonalcoholic fatty liver disease and chronic heart failureДрапкинаО. М.DrapkinaO. M.noemail@neicon.ruЗятенковаЕ. В.ZyatenkovaE. V.noemail@neicon.ruГосударственный научно-исследовательский центр профилактической медицины, МоскваРоссияNational Research Center for Preventive Medicine, MoscowRussian FederationПервый Московский государственный медицинский университет им. И.М. СеченоваРоссияFirst Moscow State Medical University named after I.M. SechenovRussian Federation201530122015013118123Copyright © Драпкина О.М., Зятенкова Е.В., 20152015Драпкина О.М., Зятенкова Е.В.Drapkina O.M., Zyatenkova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/347

В настоящее время в рутинной клинической практике измерение СКФ при отсутствии факторов риска развития ХБП не распространено. Однако данные последних исследований показывают, что пациентам с НАЖБП необходимо оценивать СКФ даже при отсутствии классических факторов риска развития ХБП. Раннее выявление поражения почек у пациентов с ХСН и НАЖБП позволит подобрать правильные дозы лекарственных средств, избегая передозировки препаратов.

Summary: in the present-day routine clinical practice, measurement of GFR in the absence of risk factors for the development of CKD is not common. However, recent research shows that evaluation of GFR in patients with NAFLD is imperative even in the absence of classical risk factors for CKD. Early detection of kidney damage in patients with CHF and NAFLD will enable to define the right dose of pharmacotherapy and avoid overdose.

ХСННАЖБПфиброз печенистеатоз печени СКФхроническая болезнь почекN-терминальный пропептид коллагена III типаFatty Liver IndexNAFLD Fibrosis ScoreReferencesРоссийские национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Клиническая нефрология. 2012. 4: 4-26.Российские национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Клиническая нефрология. 2012. 4: 4-26.Targher G, BertoLini L, RodeLLa S, Lippi G, Zoppini G, ChonchoL M. ReLationship between kidney function and Liver histoLogy in subjects with nonaLcohoLic steatohepatitis. Clin J Am Soc Nephrol, 2010. 5(12): 2166-2171.Targher G, BertoLini L, RodeLLa S, Lippi G, Zoppini G, ChonchoL M. ReLationship between kidney function and Liver histoLogy in subjects with nonaLcohoLic steatohepatitis. Clin J Am Soc Nephrol, 2010. 5(12): 2166-2171.Hwang ST, Cho YK, Yun JW, et aL. Impact of nonaLcohoLic fatty Liver disease on microaLbuminu-ria in patients with prediabetes and diabetes. InternaL Medicine JournaL, 2010. 40(6): 437-442.Hwang ST, Cho YK, Yun JW, et aL. Impact of nonaLcohoLic fatty Liver disease on microaLbuminu-ria in patients with prediabetes and diabetes. InternaL Medicine JournaL, 2010. 40(6): 437-442.MikoLasevic I, Racki S, Bubic I, JeLic I, Stimac D, OrLic L. Chronic kidney disease and nonaLcohoLic Fatty Liver disease proven by transient eLas-tography. Kidney Blood Press Res, 2013. 37(4-5): 305-310.MikoLasevic I, Racki S, Bubic I, JeLic I, Stimac D, OrLic L. Chronic kidney disease and nonaLcohoLic Fatty Liver disease proven by transient eLas-tography. Kidney Blood Press Res, 2013. 37(4-5): 305-310.MikoLasevic I, Racki S, Bubic I, JeLic I, Stimac D, OrLic L. NonaLcohoLic fatty Liver disease (NAFLD) - a new factor that interpLays between infLammation, maLnutrition, and atheroscLerosis in eLderLy hemodiaLysis patients. Clin IntervAging, 2014 Aug 7. 9: 1295-303.MikoLasevic I, Racki S, Bubic I, JeLic I, Stimac D, OrLic L. NonaLcohoLic fatty Liver disease (NAFLD) - a new factor that interpLays between infLammation, maLnutrition, and atheroscLerosis in eLderLy hemodiaLysis patients. Clin IntervAging, 2014 Aug 7. 9: 1295-303.Targher G, ChonchoL M, Zoppini G, Abaterusso C, Bonora E.Risk of chronic kidney disease in patients with non-aLcohoLic fatty Liver disease: is there a Link? J Hepatol, 2011. 54(5): 1020-9.Targher G, ChonchoL M, Zoppini G, Abaterusso C, Bonora E.Risk of chronic kidney disease in patients with non-aLcohoLic fatty Liver disease: is there a Link? J Hepatol, 2011. 54(5): 1020-9.Joachim H Ix, Sharma K. Mechanisms Linking obesity, chronic kidney disease, and fatty Liver disease: the roLes of fetuin-A, adiponectin, and AMPK. JournaL of the American Society of NephroLogy. 2010. 21(3): 406-412.Joachim H Ix, Sharma K. Mechanisms Linking obesity, chronic kidney disease, and fatty Liver disease: the roLes of fetuin-A, adiponectin, and AMPK. JournaL of the American Society of NephroLogy. 2010. 21(3): 406-412.Барышева О.Ю., Голубева А.М., Везикова Н.Н., Хейфец Л.М. Диагностика и лечение неалкогольной жировой болезни печени (обзор рекомендаций AASLD, ACG, AGA 2012).Барышева О.Ю., Голубева А.М., Везикова Н.Н., Хейфец Л.М. Диагностика и лечение неалкогольной жировой болезни печени (обзор рекомендаций AASLD, ACG, AGA 2012).AnguLo P, Hui J, Marchesini G et aL. The NAFLD Fibrosis Score: A Noninvasive System That Identifies Liver Fibrosis in Patients with NAFLD. Hepatology, 2007. 4(45): 846-854.AnguLo P, Hui J, Marchesini G et aL. The NAFLD Fibrosis Score: A Noninvasive System That Identifies Liver Fibrosis in Patients with NAFLD. Hepatology, 2007. 4(45): 846-854.GastaLdeLLi A, Kozakova M, HojLund K, FLyvbjerg A, Favuzzi A, Mitrakou A, BaLkau B. Fatty Liver is associated with insuLin resistance, risk of coronary heart disease, and earLy atheroscLerosis in a Large European popuLation. HepatoLogy 2009: 49: 1537-1544.GastaLdeLLi A, Kozakova M, HojLund K, FLyvbjerg A, Favuzzi A, Mitrakou A, BaLkau B. Fatty Liver is associated with insuLin resistance, risk of coronary heart disease, and earLy atheroscLerosis in a Large European popuLation. HepatoLogy 2009: 49: 1537-1544.BaLkau B, Lange C, VoL S, Fumeron F, Bonnet F. Nineyear incident diabetes is predicted by fatty Liver indices: the French D.E.S.I.R. study. BMC Gastroenterol, 2010. 10: 56 doi: 10.1186/1471-230x-10-56.BaLkau B, Lange C, VoL S, Fumeron F, Bonnet F. Nineyear incident diabetes is predicted by fatty Liver indices: the French D.E.S.I.R. study. BMC Gastroenterol, 2010. 10: 56 doi: 10.1186/1471-230x-10-56.CaLori G, Lattuada G, Ragogna F, Garancini MP, Crosignani P, ViLLa M, Bosi E, RuotoLo G, Piemonti L, Perseghin G. Fatty Liver index and mortaLity: the Cremona study in the 15th year of foLLow-up. Hepatology, 2011. 54: 145-152.CaLori G, Lattuada G, Ragogna F, Garancini MP, Crosignani P, ViLLa M, Bosi E, RuotoLo G, Piemonti L, Perseghin G. Fatty Liver index and mortaLity: the Cremona study in the 15th year of foLLow-up. Hepatology, 2011. 54: 145-152.Arimoto T, Takeishi Y, Niizeki T, Nozaki N, Hirono O, Watanabe T, et aL. Cardiac sympathetic denervation and ongoing myocardiaL damage for prognosis in earLy stages of heart faiLure. J Card FaiL, 2007. 13: 34-41.Arimoto T, Takeishi Y, Niizeki T, Nozaki N, Hirono O, Watanabe T, et aL. Cardiac sympathetic denervation and ongoing myocardiaL damage for prognosis in earLy stages of heart faiLure. J Card FaiL, 2007. 13: 34-41.Niizeki T, Takeishi Y, Arimoto T, Takabatake N, Nozaki N, Hirono O, et aL. Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardiaL damage in chronic heart faiLure patients. J Card FaiL, 2007. 13: 120-127.Niizeki T, Takeishi Y, Arimoto T, Takabatake N, Nozaki N, Hirono O, et aL. Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardiaL damage in chronic heart faiLure patients. J Card FaiL, 2007. 13: 120-127.Драпкина О.М., Драпкина Ю.С. Фиброз сердца и печени: составляющие одного уравнения. Кардиология, 2014. 9: 4-8.Драпкина О.М., Драпкина Ю.С. Фиброз сердца и печени: составляющие одного уравнения. Кардиология, 2014. 9: 4-8.Драпкина О.М., Ивашкин В.Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (результаты открытого многоцентрового исследования-наблюдения DIREG L 01903). Российский журнал гастроэнтерологии, гепа-тологии, колопроктологии, 2014. 4(4): 32-38.Драпкина О.М., Ивашкин В.Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (результаты открытого многоцентрового исследования-наблюдения DIREG L 01903). Российский журнал гастроэнтерологии, гепа-тологии, колопроктологии, 2014. 4(4): 32-38.Drapkina ОМ, Ivashkin VT. Liver disease structure expLored in russian federation nationaL-wide direg-L-01903 study for non-aLcohoLic fatty Liver disease screening. Journal of Hepatology, 2011. March; VoL. 54, S332.Drapkina ОМ, Ivashkin VT. Liver disease structure expLored in russian federation nationaL-wide direg-L-01903 study for non-aLcohoLic fatty Liver disease screening. Journal of Hepatology, 2011. March; VoL. 54, S332.Ivashkin V, Drapkina O, Ashikhmin Y. PrevaLence and risk factors for non-aLcohoLic fatty Liver disease in Russian Federation. Journal of Hepatology, 2010, 52: 138-139.Ivashkin V, Drapkina O, Ashikhmin Y. PrevaLence and risk factors for non-aLcohoLic fatty Liver disease in Russian Federation. Journal of Hepatology, 2010, 52: 138-139.Shen Z, Munker S, Luo F, Ma H, Yu C, Li Y Effect of Non-ALcohoLic Fatty Liver Disease on Estimated GLomeruLar FiLtration Rate CouLd Be Dependent on Age. PLoS One, 2015. Jun 18. 10(6):e0130614. doi: 10.1371/journaL. pone.0130614. eCoLLection 2015.Shen Z, Munker S, Luo F, Ma H, Yu C, Li Y Effect of Non-ALcohoLic Fatty Liver Disease on Estimated GLomeruLar FiLtration Rate CouLd Be Dependent on Age. PLoS One, 2015. Jun 18. 10(6):e0130614. doi: 10.1371/journaL. pone.0130614. eCoLLection 2015.Machado MV, GongaLves S, Carepa F, Coutinho J, Costa A, Cortez-Pinto H. Impaired renaL function in morbid obese patients with nonaLcohoLic fatty Liver disease. Liver Int, 2012. 32: 241248. doi: 10.1111/j.1478-3231.2011.02623.Machado MV, GongaLves S, Carepa F, Coutinho J, Costa A, Cortez-Pinto H. Impaired renaL function in morbid obese patients with nonaLcohoLic fatty Liver disease. Liver Int, 2012. 32: 241248. doi: 10.1111/j.1478-3231.2011.02623.Драпкина О.М., Гегенава Б.Б. Фиброз миокарда у больных с сахарным диабетом. Рациональная фармакотерапия в кардиологии, 2013. 9(1): 58-61.Драпкина О.М., Гегенава Б.Б. Фиброз миокарда у больных с сахарным диабетом. Рациональная фармакотерапия в кардиологии, 2013. 9(1): 58-61.Драпкина О. М., Дуболазова Ю. В. Применение биологических маркеров в диагностике диа-столической сердечной недостаточности. Сердечная недостаточность, 2011. 12(6): 364-372.Драпкина О. М., Дуболазова Ю. В. Применение биологических маркеров в диагностике диа-столической сердечной недостаточности. Сердечная недостаточность, 2011. 12(6): 364-372.Drapkina O, Deeva T, Ivashkin V. Patients with metaboLic syndrome and NAFLD: Assessment of obesity and heart fibrosis degree. Journal of Hepatology, 2015, 62: 735.Drapkina O, Deeva T, Ivashkin V. Patients with metaboLic syndrome and NAFLD: Assessment of obesity and heart fibrosis degree. Journal of Hepatology, 2015, 62: 735.Korneeva ON, Drapkina OM, Ivashkin VT. Predictive vaLue of epicardiaL fat as new marker of metaboLic syndrome and earLy vascuLar damage in patient with nafLd. Journal of Hepatology, 2013, 58: 543.Korneeva ON, Drapkina OM, Ivashkin VT. Predictive vaLue of epicardiaL fat as new marker of metaboLic syndrome and earLy vascuLar damage in patient with nafLd. Journal of Hepatology, 2013, 58: 543.Drapkina ОМ, Ivashkin VT. IACE in treatment of arteriaL hypertention in patients with non aLcohoLic fatty Liver. Journal of Hepatology, 2011, 54: 332-333.Drapkina ОМ, Ivashkin VT. IACE in treatment of arteriaL hypertention in patients with non aLcohoLic fatty Liver. Journal of Hepatology, 2011, 54: 332-333.Drapkina ОМ, Ivashkin VT. S-ademetionine (same) and simvastatin in patients with nonaLcohoLic fatty Liver disease and metaboLic syndrome. Journal of Hepatology, 2012, 56: 507.Drapkina ОМ, Ivashkin VT. S-ademetionine (same) and simvastatin in patients with nonaLcohoLic fatty Liver disease and metaboLic syndrome. Journal of Hepatology, 2012, 56: 507.AnguLo P. Use of ursodeoxychoLic acid in patients with Liver disease. Curr Gastroenterol Rep, 2002. 4: 37-44.AnguLo P. Use of ursodeoxychoLic acid in patients with Liver disease. Curr Gastroenterol Rep, 2002. 4: 37-44.von HaehLing S, SchefoLd JC, Jankowska EA et aL. UrsodeoxychoLic Acid in Patients With Chronic Heart FaiLure. A DoubLe-BLind, Randomized, PLacebo-ControLLed, Crossover TriaL. J Am Coll Cardiol, 2012. 59: 585-92.von HaehLing S, SchefoLd JC, Jankowska EA et aL. UrsodeoxychoLic Acid in Patients With Chronic Heart FaiLure. A DoubLe-BLind, Randomized, PLacebo-ControLLed, Crossover TriaL. J Am Coll Cardiol, 2012. 59: 585-92.BahrLe S, Szabo G, StiehL A et aL. Adjuvant treatment with ursodeoxychoLic acid may reduce the incidence of acute cardiac aLLograft ejection. J Heart Lung Transplant, 1998. 17: 592- 8.BahrLe S, Szabo G, StiehL A et aL. Adjuvant treatment with ursodeoxychoLic acid may reduce the incidence of acute cardiac aLLograft ejection. J Heart Lung Transplant, 1998. 17: 592- 8.Paumgartner G, Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxy-choLic acid in choLestatic Liver disease. Clin Liver Dis, 2004. 8: 67-81.Paumgartner G, Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxy-choLic acid in choLestatic Liver disease. Clin Liver Dis, 2004. 8: 67-81.Korneeva ON, Drapkina OM, Ivashkin VT. Simvastatin and ursodeoxychoLic acid in patients with nonaLcohoLic fatty Liver disease and metaboLic syndrome Journal of Hepatology, 2010, 52: 146.Korneeva ON, Drapkina OM, Ivashkin VT. Simvastatin and ursodeoxychoLic acid in patients with nonaLcohoLic fatty Liver disease and metaboLic syndrome Journal of Hepatology, 2010, 52: 146.Suzuki A, Lymp J, Sauver JS, AnguLo P, Lindor K. VaLues and Limitations of serum aminotrans-ferases in cLinicaL triaLs of nonaLcohoLic steato-hepatitis. Liver Int, 2006. 26: 1209-1216.Suzuki A, Lymp J, Sauver JS, AnguLo P, Lindor K. VaLues and Limitations of serum aminotrans-ferases in cLinicaL triaLs of nonaLcohoLic steato-hepatitis. Liver Int, 2006. 26: 1209-1216.Ratziu V, de Ledinghen V, Oberti F, Mathurin P WarteLLe-BLadou C, Renou C et aL. FRESGUN. A randomized controLLed triaL of high-dose ursodesoxychoLic acid for nonaLcohoLic steatohepatitis. J Hepatol, 2011. 54: 1011-1019.Ratziu V, de Ledinghen V, Oberti F, Mathurin P WarteLLe-BLadou C, Renou C et aL. FRESGUN. A randomized controLLed triaL of high-dose ursodesoxychoLic acid for nonaLcohoLic steatohepatitis. J Hepatol, 2011. 54: 1011-1019.Banu D. OzeL Coskin at aL. Effects of ursodeoxychoLic acid therapy on carotid intima media thickness, apoLipoprotein A1, apoLipoprotein B, and apoLipoprotein B/A1 ratio in nonaLcohoLic steatohepatitis. Eur. J. Gastroenterol Hepatol 2015, 27: 142-149.Banu D. OzeL Coskin at aL. Effects of ursodeoxychoLic acid therapy on carotid intima media thickness, apoLipoprotein A1, apoLipoprotein B, and apoLipoprotein B/A1 ratio in nonaLcohoLic steatohepatitis. Eur. J. Gastroenterol Hepatol 2015, 27: 142-149.

The authors declare that there are no conflicts of interest present.